FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Clinical trials for FOCAL SEGMENTAL GLOMERULOSCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new FOCAL SEGMENTAL GLOMERULOSCLEROSIS trials appear
Sign up with your email to follow new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise in slowing kidney disease for FSGS patients
Disease control CompletedThis study tested a new medicine called sparsentan in 371 people with a rare kidney disease called FSGS. The goal was to see if it could slow down kidney damage better than a standard blood pressure pill. Participants took either sparsentan or the standard drug for two years, and…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
New drug aims to reduce kidney damage in rare diseases
Disease control CompletedThis study tested a new drug called R3R01 in 43 people with two rare kidney diseases: Alport syndrome and focal segmental glomerulosclerosis (FSGS). The goal was to see if the drug is safe and can lower protein in the urine, a sign of kidney damage. Participants had uncontrolled …
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated May 26, 2026 08:39 UTC
-
New hope for FSGS patients: preemptive rituximab may stop kidney disease return
Prevention CompletedThis early-phase study tested whether giving a combination of plasmapheresis (a blood-filtering procedure) and the drug rituximab before or at the time of kidney transplant could prevent focal segmental glomerulosclerosis (FSGS) from recurring. The study enrolled 21 children and …
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: University of Minnesota • Aim: Prevention
Last updated May 22, 2026 14:02 UTC
-
Scientists hunt for genes behind kidney disease that strikes black patients more often
Knowledge-focused CompletedThis study aims to find genetic markers that may increase the risk of developing focal segmental glomerulosclerosis (FSGS), a kidney disease that can lead to kidney failure. Researchers will compare DNA from 616 people, including African-Americans with FSGS, African-Americans wit…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated May 26, 2026 08:41 UTC